HK1217292A1 - 基於k- ras的突变状态治疗癌症的方法 - Google Patents

基於k- ras的突变状态治疗癌症的方法 Download PDF

Info

Publication number
HK1217292A1
HK1217292A1 HK16105270.2A HK16105270A HK1217292A1 HK 1217292 A1 HK1217292 A1 HK 1217292A1 HK 16105270 A HK16105270 A HK 16105270A HK 1217292 A1 HK1217292 A1 HK 1217292A1
Authority
HK
Hong Kong
Prior art keywords
treating cancer
ras
mutation status
cancer based
status
Prior art date
Application number
HK16105270.2A
Other languages
English (en)
Chinese (zh)
Inventor
Daniel Pierce
Carrie BRACHMANN
Original Assignee
Abraxis Bioscience, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience, Llc filed Critical Abraxis Bioscience, Llc
Publication of HK1217292A1 publication Critical patent/HK1217292A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
HK16105270.2A 2013-01-11 2014-01-10 基於k- ras的突变状态治疗癌症的方法 HK1217292A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361848793P 2013-01-11 2013-01-11
US61/848793 2013-01-11
US201361752417P 2013-01-14 2013-01-14
US61/752417 2013-01-14
US13/794,712 US20140199405A1 (en) 2013-01-11 2013-03-11 Method for treating cancer based on mutation status of k-ras
US13/794712 2013-03-11
PCT/US2014/011097 WO2014110408A1 (en) 2013-01-11 2014-01-10 Method for treating cancer based on mutation status of k-ras

Publications (1)

Publication Number Publication Date
HK1217292A1 true HK1217292A1 (zh) 2017-01-06

Family

ID=51165319

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105270.2A HK1217292A1 (zh) 2013-01-11 2014-01-10 基於k- ras的突变状态治疗癌症的方法

Country Status (12)

Country Link
US (1) US20140199405A1 (https=)
EP (1) EP2943184A4 (https=)
JP (1) JP2016506908A (https=)
KR (1) KR20150103746A (https=)
AU (1) AU2014205254A1 (https=)
BR (1) BR112015016466A2 (https=)
CA (1) CA2897581A1 (https=)
HK (1) HK1217292A1 (https=)
IL (1) IL239740A0 (https=)
MX (1) MX2015008889A (https=)
WO (1) WO2014110408A1 (https=)
ZA (1) ZA201504878B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103405405A (zh) 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR101420445B1 (ko) 2005-08-31 2014-07-16 아브락시스 바이오사이언스, 엘엘씨 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물
ES2421354T3 (es) 2006-08-11 2013-08-30 Johns Hopkins University Secuencias consenso codificantes de cánceres de mama y colorrectales humanos
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
JP5579057B2 (ja) * 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
HRP20192259T1 (hr) 2009-04-15 2020-03-06 Abraxis Bioscience, Llc Pripravci nanočestica bez priona i metode njihove proizvodnje
CA3051495A1 (en) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
JP6038123B2 (ja) 2011-04-28 2016-12-07 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物の脈管内送達およびそれらの使用
JP6216721B2 (ja) 2011-12-14 2017-10-18 アブラクシス バイオサイエンス， エルエルシー 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
EP3369432A1 (en) 2013-12-09 2018-09-05 Targovax Asa A peptide mixture
CA2947963A1 (en) 2014-05-06 2015-11-12 Targovax Asa Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
PL3998069T3 (pl) 2015-06-29 2025-03-31 Abraxis Bioscience, Llc Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych
BR112019006329A2 (pt) * 2016-10-07 2019-06-25 Abraxis Bioscience Llc métodos de tratamento de câncer do trato biliar
EP3444272A1 (en) * 2017-08-17 2019-02-20 International-Drug-Development-Biotech Treatment of ck8 positive cancers in relation with k-ras gene status
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
JP7832108B2 (ja) 2019-10-28 2026-03-17 アブラクシス バイオサイエンス， エルエルシー アルブミンおよびラパマイシンの医薬組成物
US20230172935A1 (en) * 2020-05-08 2023-06-08 Cardiff Oncology, Inc. Methods of monitoring kras mutations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1853250T1 (sl) * 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
PL1913157T5 (pl) * 2005-06-28 2017-09-29 Genentech Inc Mutacje EGFR i KRAS do prognozowania reakcji pacjenta na leczenie inhibitorem EGFR
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
AR065687A1 (es) * 2007-03-13 2009-06-24 Amgen Inc Metodo para determinar la presencia o no de una mutacion k-ras y terapia con anticuerpos anti-egfr
WO2011116181A1 (en) * 2010-03-17 2011-09-22 Caris Life Sciences, Inc. Theranostic and diagnostic methods using sparc and hsp90
PL2470173T3 (pl) * 2009-08-25 2016-11-30 Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog
NZ717490A (en) * 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
WO2011127219A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
WO2011146803A1 (en) * 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
JP6038128B2 (ja) * 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
EP2823306A4 (en) * 2012-03-09 2015-11-11 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
AU2013201584A1 (en) * 2012-03-12 2013-09-26 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody

Also Published As

Publication number Publication date
IL239740A0 (en) 2015-08-31
BR112015016466A2 (pt) 2017-07-11
EP2943184A1 (en) 2015-11-18
ZA201504878B (en) 2016-10-26
KR20150103746A (ko) 2015-09-11
MX2015008889A (es) 2015-11-13
CA2897581A1 (en) 2014-07-17
AU2014205254A1 (en) 2015-07-23
JP2016506908A (ja) 2016-03-07
EP2943184A4 (en) 2016-07-20
US20140199405A1 (en) 2014-07-17
WO2014110408A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
HK1217292A1 (zh) 基於k- ras的突变状态治疗癌症的方法
HK1217180A1 (zh) 根據一種核苷轉運載體的水平治療癌症的方法
HK1220405A1 (zh) 治疗膀胱癌的方法
AU2022231657A1 (en) Compositions and Methods for Treating Cancer
MX370662B (es) Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer.
HK1219231A1 (zh) 治疗儿童实体瘤的方法
HK1247092A1 (zh) 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
EP3291832A4 (en) Nanoparticle compositions for sustained therapy
PH12016502066A1 (en) Methods of treating bladder cancer
MX2021002455A (es) Metodos para tratar tumores de celulas epitelioides.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
HK1220155A1 (zh) 治疗癌症的方法
MX364637B (es) Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
EP3277270A4 (en) Compositions and methods for treating anemia
HK1245158A1 (zh) 阿吡莫德组合物及其使用方法
HK1250944A1 (zh) 用於治疗癌症的方法
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
HK1255835A1 (zh) 用於治疗乙型肝炎的治疗组合物及方法
IL250844A0 (en) Medical nanoparticles and related preparations, methods and systems
EP3381472A4 (en) MEDICINAL PRODUCTS FOR THE TREATMENT OR PREVENTION OF DISTURBANCES CAUSED BY TGF SIGNALS AND USE THEREOF
EP3188800A4 (en) Compositions and methods for treating fibrosing disorders and cancer
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
EP3181137A4 (en) Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3